The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of clinical trial enrollment on episode costs in the Oncology Care Model (OCM).
 
Garrett Young
Employment - OneOncology
Consulting or Advisory Role - Genentech; GlaxoSmithKline
 
Larry Edward Bilbrey
No Relationships to Disclose
 
Edward Arrowsmith
Employment - Tennessee Oncology
Stock and Other Ownership Interests - OneOncology
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calistoga Pharmaceuticals (Inst); Celgene (Inst); Cephalon (Inst); Chorus (Inst); Clovis Oncology (Inst); Cougar Biotechnology (Inst); Eisai (Inst); EMD Serono (Inst); Evelo Biosciences (Inst); Exelixis (Inst); Genentech (Inst); Gilead Sciences (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); Janssen Research & Development (Inst); Lilly (Inst); Merck (Inst); Millennium (Inst); Modra Pharmaceuticals (Inst); Novartis (Inst); Oncogenex (Inst); Onyx (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Sarah Cannon Research Institute (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Flatiron Health; OneOncology; Sarah Cannon Research Institute
Other Relationship - Sarah Cannon Research Institute
 
L. Johnetta Blakely
Employment - Tennessee Oncology
Leadership - HCA Healthcare
Consulting or Advisory Role - GRAIL
Research Funding - Bristol-Myers Squibb
 
Davey B. Daniel
Research Funding - Abbvie (Inst); Amgen (Inst); ARMO BioSciences (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo (Inst); G1 Therapeutics (Inst); G1 Therapeutics (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Guardant Health (Inst); Immunomedics (Inst); Janssen Research & Development (Inst); Lilly (Inst); Merck (Inst); Merus NV (Inst); Novartis (Inst); Novartis (Inst); Roche (Inst); Roche (Inst); Roche (Inst)
 
Andrew Yue
Employment - Tuple Health
Stock and Other Ownership Interests - 3M; Tuple Health
 
Basit Iqbal Chaudhry
Employment - Johns Hopkins Hospital (I); Mary's Center (I); Tuple Health
Leadership - Navitus (I); Paladina Health (I); Personal Genome Diagnostics (I); Radiology Partners (I); SelectQuote (I); Sigilon Therapeutics (I); Strive Health (I)
Stock and Other Ownership Interests - Audax (I); Bright Health (I); Eargo (I); Navitus (I); Paladina Health (I); Personal Genome Diagnostics (I); Radiology Partners (I); SelectQuote (I); Sigilon Therapeutics (I); Strive Health (I); Tuple Health
Honoraria - Northeast Business Group on Health (I)
Consulting or Advisory Role - ASPEN Group (I); Epic (I); Mount Sinai Health System (I); NBC Universal (I); New Enterprise Associates (I); Yahoo News/Verizon Media (I)
 
David R. Spigel
Leadership - ASCO (Inst)
Consulting or Advisory Role - Amgen (Inst); Aptitude Health (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Curio Science (Inst); Dracen (Inst); EMD Serono (Inst); Evelo Therapeutics (Inst); Exelixis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Iksuda Therapeutics (Inst); Illumina (Inst); Intellisphere (Inst); Ipsen (Inst); Jazz Pharmaceuticals (Inst); Merck (Inst); Mirati Therapeutics (Inst); Molecular Templates (Inst); Nektar (Inst); Novartis (Inst); Novocure (Inst); Pfizer (Inst); PharmaMar (Inst); Puma Biotechnology (Inst); Regeneron (Inst); Sanofi/Aventis (Inst); Seagen (Inst); Takeda (Inst); TRIPTYCH Health Partners (Inst); TRM Oncology (Inst)
Research Funding - Aeglea Biotherapeutics (Inst); Agios (Inst); Apollomics (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); BIND Therapeutics (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celgene (Inst); Celldex (Inst); Clovis Oncology (Inst); cyteir (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Elevation Oncology (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); GRAIL (Inst); ImClone Systems (Inst); Immunogen (Inst); Ipsen (Inst); Janssen Oncology (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Molecular Partners (Inst); Nektar (Inst); Neon Therapeutics (Inst); Novartis (Inst); Novocure (Inst); Takeda (Inst); Tesaro (Inst); Transgene (Inst); University of Texas Southwestern Medical Center - Simmons Cancer Center (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Genentech; Novartis
 
Aaron J. Lyss
Employment - OneOncology
Honoraria - Abbvie/Genentech; American Journal of Managed Care; Amgen; Avalere Health; EMD Serono; Genentech; Heron; McGivney Global Advisors; Pfizer
Speakers' Bureau - Genentech/Roche
 
Natalie R. Dickson
Employment - Tennessee Oncology
Consulting or Advisory Role - Abbvie; Cigna; Via Oncology
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Flatiron Health; Flatiron Health
 
John Fox
No Relationships to Disclose
 
Stephen Matthew Schleicher
Employment - Tennessee Oncology
Leadership - OneOncology
Consulting or Advisory Role - Bayer; Daiichi Sankyo; Magnolia Innovation; Rigel
Research Funding - Tennessee Oncology
Travel, Accommodations, Expenses - Flatiron Health; Magnolia Innovation; Rigel; Tennessee Oncology
 
Lee S. Schwartzberg
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; BeyondSpring Pharmaceuticals; Bristol-Myers Squibb; Genentech; Helsinn Therapeutics; Lilly; Myriad Genetics; Napo Pharmaceuticals; Odonate Therapeutics; Pfizer; Spectrum Pharmaceuticals
Speakers' Bureau - Coherus Biosciences; Merck; Puma Biotechnology; Seagen
Research Funding - Amgen (Inst); Pfizer (Inst)